Mouse models of influenza infection with circulating strains to test seasonal vaccine efficacy

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Groves, Helen T ^a   McDonald, Jacqueline U ^a   Langat, Pinky ^a   Kinnear, Ekaterina ^a   Kellam, Paul ^a   McCauley, John ^b   Ellis, Joanna ^c   Thompson, Catherine ^c   Elderfield, Ruth ^a   Parker, Lauren ^a   Barclay, Wendy ^a   Tregoning, John S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antibodies; Infection; Influenza Vaccines; Mouse models; Vaccine drift; Viral

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGENIC VARIATION; ARTICLE; BODY WEIGHT LOSS; CD8+ T LYMPHOCYTE; CELL ISOLATION; CIRCULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; IMMUNIZATION; INFLUENZA; MOUSE; NONHUMAN; PANDEMIC; PHYLOGENETIC TREE; PLAQUE ASSAY; PNEUMONIA; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFLAMMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASON; SEASONAL INFLUENZA; VIRUS LOAD;

EID: 85041584839     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00126     Document Type: Article

References (36)

1. WHO. (2016). WHO | Influenza (Seasonal) [Online]. World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/[Accessed].
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine (2007) 25:5086-96. doi:10.1016/j.vaccine.2007.03.046
3. Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health (2014) 14:813. doi:10.1186/1471-2458-14-813
4. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med (2013) 11:153. doi:10.1186/1741-7015-11-153
5. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-16 influenza season. Am J Transplant (2015) 15:2767-75. doi:10.1111/ajt.13505
6. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis (2009) 199:159-67. doi:10.1086/595861
7. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis (2012) 55:951-9. doi:10.1093/cid/cis574
8. Xie H, Wan XF, Ye Z, Plant EP, Zhao Y, Xu Y, et al. H3N2 Mismatch of 2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci Rep (2015) 5:15279. doi:10.1038/srep15279
9. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep (2015) 64:10-5.
10. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill (2015) 20(4):20122. doi:10.2807/1560-7917.ES2015.20.4.21022
11. WHO. (2014). World Health Organization Influenza Centre London: Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2015 [Online]. Available from: https://crick.ac.uk/media/221823/nimr-vcm-report-sep-14-web.pdf [Accessed].
12. Elderfield RA, Watson SJ, Godlee A, Adamson WE, Thompson CI, Dunning J, et al. Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. J Virol (2014) 88:13269-83. doi:10.1128/JVI.01636-14
13. WHO. (2017). WHO recommendations on the composition of influenza virus vaccines. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/en/
14. Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, et al. Integrating influenza antigenic dynamics with molecular evolution. Elife (2014) 3:e01914. doi:10.7554/eLife.01914
15. Smith DJ, Lapedes AS, De Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, et al. Mapping the antigenic and genetic evolution of influenza virus. Science (2004) 305:371-6. doi:10.1126/science.1097211
16. Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A (2014) 111:15798-803. doi:10.1073/pnas.1409171111
17. Huang KY, Rijal P, Schimanski L, Powell TJ, Lin TY, Mccauley JW, et al. Focused antibody response to influenza linked to antigenic drift. J Clin Invest (2015) 125:2631-45. doi:10.1172/JCI81104
18. Hussell T, Pennycook A, Openshaw PJM. Inhibition of tumour necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol (2001) 31:2566-73. doi:10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
19. McDonald JU, Zhong Z, Groves HT, Tregoning JS. Inflammatory responses to influenza vaccination at the extremes of age. Immunology (2017) 151:451-63. doi:10.1111/imm.12742
20. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A (2012) 109:21474-9. doi:10.1073/pnas.1218841110
21. Shi Y, Wu Y, Zhang W, Qi J, Gao GF. Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Micro (2014) 12:822-31. doi:10.1038/nrmicro3362
22. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, et al. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol (2006) 80:7469-80. doi:10.1128/JVI.02677-05
23. Wang Q, Tian X, Chen X, Ma J. Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc Nat Acad Sci U S A (2007) 104:16874-9. doi:10.1073/pnas.0708363104
24. Gould VMW, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front Microbiol (2017) 8:900. doi:10.3389/fmicb.2017.00900
25. Poon LLM, Song T, Rosenfeld R, Lin X, Rogers MB, Zhou B, et al. Quantifying influenza virus diversity and transmission in humans. Nat Genet (2016) 48:195-200. doi:10.1038/ng.3479
26. Sobel Leonard A, Weissman DB, Greenbaum B, Ghedin E, Koelle K. Transmission bottleneck size estimation from pathogen deep-sequencing data, with an application to human influenza A virus. J Virol (2017) 91:e171-117. doi:10.1128/JVI.00171-17
27. Frise R, Bradley K, Van Doremalen N, Galiano M, Elderfield RA, Stilwell P, et al. Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance. Sci Rep (2016) 6:29793. doi:10.1038/srep29793
28. Russell RF, Mcdonald JU, Lambert L, Tregoning JS. Use of the microparticle NanoSiO2 as an adjuvant to boost vaccine immune responses in neonatal mice against influenza. J Virol (2016) 90:4735-44. doi:10.1128/JVI.03159-15
29. Siggins MK, Gill SK, Langford PR, Li Y, Ladhani SN, Tregoning JS. PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice. Vaccine (2015) 33:4954-61. doi:10.1016/j.vaccine.2015.07.034
30. Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology (2004) 321:144-53. doi:10.1016/j.virol.2003.12.009
31. Donnelly L, Curran RM, Tregoning JS, Mckay PF, Cole T, Morrow RJ, et al. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine (2011) 29:4512-20. doi:10.1016/j.vaccine.2011.04.023
32. Drummond AJ, Suchard MA, Xie D, Rambaut A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol (2012) 29:1969-73. doi:10.1093/molbev/mss075
33. Lewis NS, Russell CA, Langat P, Anderson TK, Berger K, Bielejec F, et al. The global antigenic diversity of swine influenza A viruses. Elife (2016) 5:e12217. doi:10.7554/eLife.12217
34. Squires RB, Noronha J, Hunt V, Garcia-Sastre A, Macken C, Baumgarth N, et al. Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 6:404-16. doi:10.1111/j.1750-2659.2011.00331.x
35. Bogner P, Capua I, Lipman DJ, Cox NJ, et al. A global initiative on sharing avian flu data. Nature (2006) 442:981-981. doi:10.1038/442981a
36. Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng (2007) 9:90-5. doi:10.1109/MCSE.2007.55